Anika Therapeutics To Issue Third-Quarter 2017 Financial Results And Business Highlights On Wednesday, October 25 Post author:Sam Post published:October 11, 2017 Post category:BioPharma BEDFORD, Mass.–(BUSINESS WIRE)–Anika … Source: BioSpace You Might Also Like Pfizer Announces FDA Approval of XELJANZ (tofacitinib) and XELJANZ XR for the Treatment of Active… December 14, 2017 Tauriga Secures Investment Of $80,000 USD Through A 5% Promissory Note With Fixed Conversion Price Of $0.00125 Per Share June 29, 2017 FDA Puts in Place New Hiring Protocols for Foreign Scientists August 13, 2017
Pfizer Announces FDA Approval of XELJANZ (tofacitinib) and XELJANZ XR for the Treatment of Active… December 14, 2017
Tauriga Secures Investment Of $80,000 USD Through A 5% Promissory Note With Fixed Conversion Price Of $0.00125 Per Share June 29, 2017
